SCHEMBL23609331

SCHEMBL23609331

CN(C)CCc1cc(Nc2ccccc2)ccc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
TDP1 Q9NUW8 4/20 0.42
LMNA P02545 3/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
GFER P55789 1/20 0.42
ALDH1A1 P00352 7/20 0.42
CYP3A4 P08684 5/20 0.42
ALOX12 P18054 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
HTT P42858 1/20 0.42
TAAR1 Q96RJ0 4/20 0.41
AR P10275 1/20 0.40
HSD17B10 Q99714 4/20 0.39
ALOX15 P16050 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536379 0.83 MAPT (0.46) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL6535929 0.80 MAPT (0.43) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL30392107 0.80 MAPT (0.43) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL28958671 0.80 MAPT (0.46) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL3796679 0.79 MAPT (0.48) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL8680807 0.78 KCNH3 (0.42) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL1650229 0.78 KCNH3 (0.42) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL2904304 0.77 ALDH1A1 (0.42) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL23609635 0.76 MEN1 (0.45) MAPTMEN1KMT2ATDP1LMNA
SCHEMBL25794150 0.76 SLC6A4 (0.39) MAPTMEN1KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 US disclosed
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
EP-4125874-A1 LIPOXYGENASE INHIBITORS SRI International (US) 2023-02-08 EP disclosed
WO-2021195346-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-09-30 WO disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 MAPT 2110/4885MEN1 4539/4885KMT2A 2591/4885
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 MAPT 1601/4885MEN1 4167/4885KMT2A 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.